Biochemical And Triglyceride-Glucose Index (Tyg) Profile In High Doses Streptozotocin-Nicotinamide Produce Diabetes Mellitus In Rats Model

Abstract

Preclinical test is a stage in evaluating potential drug candidates for diabetes mellitus (DM). However, developing an animal model that accurately replicates the various pathophysiological and etiological aspects of DM as seen in humans presents significant challenges. To induce diabetes, streptozotocin (STZ) in single doses or combination with nicotinamide (NIC) is often used. Treating diabetes conditions has a low success rate, compounded by the complexity of numerous affected biochemical profiles, presenting a significant research challenge. Therefore, this research aimed to determine the biochemical and triglyceride-glucose index (TyG) profile in high doses of STZ-NIC-induced diabetes in the rat model. The population consisted of 18 rates divided into three groups, each containing six. Group I (the normal group) consisted of healthy rats who were given standard feed and drink. In groups II and III, diabetes was induced intraperitoneally with 50 and 65 mg/kg of STZ in addition to 230 mg/kg of NIC. Observations were made for 6 weeks after the rats were diagnosed with diabetes having blood glucose levels of ≥ 250 mg/dL 72 hours after STZ-NIC induction. The data were evaluated statistically by one-way analysis of variance (ANOVA), followed by the least significant difference (LSD) test (p ≤ 0.05). The result showed significant differences in blood biochemistry, specifically in the parameters of blood glucose, SGPT, and SGOT with increasing doses of STZ-NIC (p<0.05), but not in total cholesterol, triglycerides, albumin, total protein, and TyG ( p<0.05). The high doses of STZ-NIC administration can produce DM models with different blood biochemical profiles but not in TyG.